MD-18

MD-18 is a first-in-class synthetic peptide drug developed for the treatment of obesity and related metabolic conditions, including type 2 diabetes. Its mechanism of action involves modulation of protein-tyrosine phosphatase 1B (PTP1B), a key regulator in glucose metabolism and energy homeostasis. Unlike existing therapies that primarily suppress appetite, MD-18 disrupts specific protein-protein interactions to regulate PTP1B activity, aiming to improve insulin sensitivity and address underlying metabolic dysfunctions. In Phase Ia clinical trials conducted by Radella Pharmaceuticals, single subcutaneous doses were well-tolerated with no severe adverse events reported. The drug demonstrated consistent metabolic improvements such as reduced leptin levels, enhanced insulin sensitivity, and decreases in ALT, total cholesterol, and LDL cholesterol seven days post-dose[1][3][4].